Want to see HK:0455 full AI Analyst Report?
Top Page
Tianda Pharmaceuticals Ltd.
(0455)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$0.11
▼(-12.31% Downside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by weak financial performance (persistent losses, margin deterioration, and declining revenue) despite a reasonably manageable leverage position and a 2025 cash flow uptick. Technicals are supportive due to strong momentum and price above major moving averages, but the overbought RSI reduces confidence. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data to offset profitability risk.
Positive Factors
Manageable Leverage
Moderate leverage limits debt-service pressure and preserves financial flexibility relative to a heavily indebted balance sheet. This provides some resilience while management works to restore profitability, although continued losses could weaken that advantage over time.
Negative Factors
Persistent Losses
Persistent operating and net losses indicate that the current business model is not covering its full cost base. The sharp margin deterioration reduces financial resilience, limits reinvestment capacity, and raises the risk of further equity dilution.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Moderate leverage limits debt-service pressure and preserves financial flexibility relative to a heavily indebted balance sheet. This provides some resilience while management works to restore profitability, although continued losses could weaken that advantage over time.
Read all positive factors
Tianda Pharmaceuticals Ltd. (0455) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$232.20M
Dividend Yield2.26%
Average Volume (3M)71.20K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue Growth12.89%
EPS Growth-2.56%
CountryHK
Employees613
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,150,041,700
10 Day Avg. Volume114,000
30 Day Avg. Volume71,200
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.61
Price to Sales (P/S)0.86
P/FCF Ratio99.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tianda Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Founded in 1992 and headquartered in Central, Hong Kong, Tianda Pharmaceuticals Limited operates as an investment holding company and a subsidiary of Tianda Group Limited. The firm, which changed its name from Tianda Holdings Limited in September ...
Tianda Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
56
Neutral
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 322.94M | 329.94M | 532.09M | 546.69M | 509.96M |
| Gross Profit | 133.31M | 152.02M | 255.53M | 251.52M | 241.22M |
| EBITDA | -24.41M | -49.49M | 15.66M | -19.89M | -5.14M |
| Net Income | -70.00M | -61.37M | -24.16M | -54.64M | -21.67M |
Balance Sheet | |||||
| Total Assets | 747.83M | 765.02M | 917.29M | 1.09B | 1.16B |
| Cash, Cash Equivalents and Short-Term Investments | 64.81M | 85.69M | 162.44M | 343.44M | 334.00M |
| Total Debt | 132.66M | 127.44M | 113.60M | 141.05M | 160.43M |
| Total Liabilities | 291.46M | 259.36M | 325.35M | 434.23M | 375.08M |
| Stockholders Equity | 456.64M | 505.84M | 592.07M | 627.83M | 756.75M |
Cash Flow | |||||
| Free Cash Flow | 2.80M | -52.30M | -116.04M | 54.73M | -61.98M |
| Operating Cash Flow | 14.42M | -9.70M | -49.76M | 79.11M | -8.23M |
| Investing Cash Flow | -20.38M | -31.77M | -69.10M | -12.20M | 86.35M |
| Financing Cash Flow | -15.31M | -30.65M | -57.39M | -28.98M | -1.29M |
Tianda Pharmaceuticals Ltd. Technical Analysis
Positive
0.13
Price Trends
0.10
Positive
0.10
Positive
0.10
Positive
Market Momentum
<0.01
Negative
67.69
Neutral
80.61
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0455, the sentiment is Positive. The current price of 0.13 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.10, and above the 200-day MA of 0.10, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 67.69 is Neutral, neither overbought nor oversold. The STOCH value of 80.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0455.
Tianda Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$765.08M | 7.75 | 13.59% | 7.54% | 10.63% | 39.44% | |
59 Neutral | HK$1.48B | 5.53 | 6.78% | 6.40% | 6.55% | 36.62% | |
54 Neutral | HK$234.90M | -0.21 | -154.56% | ― | -7.12% | -523.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$232.20M | -6.73 | -8.05% | 2.26% | 12.89% | -2.56% | |
49 Neutral | HK$373.32M | 94.44 | 0.34% | 84.69% | -8.30% | -44.44% | |
43 Neutral | HK$144.43M | -4.83 | -21.66% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:0455
Tianda Pharmaceuticals Ltd.
0.12
-0.06
-32.75%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.08
-0.04
-33.33%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.34
-0.11
-24.44%
HK:1498
PuraPharm Corp. Ltd.
0.28
-0.18
-38.89%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
0.99
-0.18
-15.52%
HK:0239
Pak Fah Yeow International Limited
2.48
0.19
8.16%
Tianda Pharmaceuticals Ltd. Corporate Events
Tianda Pharmaceuticals Narrows Comprehensive Loss Despite Higher Interim Revenue
Aug 10, 2026
Tianda Pharmaceuticals reported interim revenue of HK$164.2 million for the six months ended 30 June 2026, up from HK$136.6 million a year earlier, driven by higher sales despite increased cost of sales and operating expenses. The company’s ...
Tianda Pharmaceuticals Sets Board Meeting to Approve 2026 Interim Results
Jul 28, 2026
Tianda Pharmaceuticals Limited has scheduled a board meeting for 10 August 2026 to approve the interim results for the six months ended 30 June 2026, signaling the imminent release of its mid-year financial performance. The announcement indicates ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.